Hengrui Pharma: Injectable SHR-A1811 and other drugs approved for clinical trials
Hengrui Pharma and its subsidiaries recently received approval from the National Medical Products Administration to conduct clinical trials for injectable SHR-A1811, Adalimumab injection, and Famitinib malate capsules. The specific study is an open-label, multicenter Phase 1b/2 clinical trial of injectable SHR-A1811 in combination with anti-tumor drugs for the treatment of solid tumors
According to the Zhitong Finance APP, Hengrui Pharma (600276.SH) announced that recently, the company and its subsidiaries Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Pharmaceutical Co., Ltd. received the approval from the National Medical Products Administration (referred to as "NMPA") for the issuance of the "Drug Clinical Trial Approval Notice" regarding the injectable SHR-A1811, Adebali monoclonal antibody injection, and fumaric acid famitinib capsules, and will soon commence clinical trials. Specifically, it involves an open-label, multicenter Phase Ib/II clinical study of injectable SHR-A1811 in combination with anti-tumor drugs for the treatment of solid tumors
